phospho myosin light chain 2 ser19 antibody  (Cell Signaling Technology Inc)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 99
    Name:
    Phospho Myosin Light Chain 2 Ser19 Antibody
    Description:
    Myosin is composed of six polypeptide chains two identical heavy chains and two pairs of light chains Myosin light chain 2 MLC2 also known as myosin regulatory light chain MRLC RLC or LC20 has many isoforms depending on its distribution In smooth muscle MLC2 is phosphorylated at Thr18 and Ser19 by myosin light chain kinase MLCK in a Ca2 calmodulin dependent manner 1 This phosphorylation is correlated with myosin ATPase activity and smooth muscle contraction 2 ROCK also phosphorylates Ser19 of smooth muscle MLC2 which regulates the assembly of stress fibers 3 Phosphorylation of smooth muscle MLC2 at Ser1 Ser2 and Ser9 by PKC and cdc2 has been reported to inhibit myosin ATPase activity 4 5 Phosphorylation by cdc2 controls the timing of cytokinesis 5 Transgenic mice lacking phosphorylation sites on the cardiac muscle isoform show morphological and functional abnormalities 6
    Catalog Number:
    3671
    Price:
    None
    Applications:
    Western Blot, Immunofluorescence
    Category:
    Primary Antibodies
    Source:
    Polyclonal antibodies are produced by immunizing animals with a synthetic phosphopeptide corresponding to residues surrounding Ser19 of human myosin light chain 2. Antibodies are purified by protein A and peptide affinity chromatography.
    Reactivity:
    Human Mouse Rat D melanogaster
    Buy from Supplier


    Structured Review

    Cell Signaling Technology Inc phospho myosin light chain 2 ser19 antibody
    Myosin is composed of six polypeptide chains two identical heavy chains and two pairs of light chains Myosin light chain 2 MLC2 also known as myosin regulatory light chain MRLC RLC or LC20 has many isoforms depending on its distribution In smooth muscle MLC2 is phosphorylated at Thr18 and Ser19 by myosin light chain kinase MLCK in a Ca2 calmodulin dependent manner 1 This phosphorylation is correlated with myosin ATPase activity and smooth muscle contraction 2 ROCK also phosphorylates Ser19 of smooth muscle MLC2 which regulates the assembly of stress fibers 3 Phosphorylation of smooth muscle MLC2 at Ser1 Ser2 and Ser9 by PKC and cdc2 has been reported to inhibit myosin ATPase activity 4 5 Phosphorylation by cdc2 controls the timing of cytokinesis 5 Transgenic mice lacking phosphorylation sites on the cardiac muscle isoform show morphological and functional abnormalities 6
    https://www.bioz.com/result/phospho myosin light chain 2 ser19 antibody/product/Cell Signaling Technology Inc
    Average 99 stars, based on 12 article reviews
    Price from $9.99 to $1999.99
    phospho myosin light chain 2 ser19 antibody - by Bioz Stars, 2020-09
    99/100 stars

    Images

    Related Articles

    Western Blot:

    Article Title: BNIP-2 retards breast cancer cell migration by coupling microtubule-mediated GEF-H1 and RhoA activation
    Article Snippet: .. Antibodies and chemicals For Western blot, primary antibody catalog numbers and dilution factors are as follows: polyclonal anti–BNIP-2 antibodies were purchased from Sigma-Aldrich (HPA026843) and GeneTex (GTX114283) or self-purified from rabbit serum, as previously described ( ); monoclonal anti–GEF-H1 (ab155785) was purchased from Abcam; monoclonal anti-RhoA was from Santa Cruz Biotechnology (sc-418); polyclonal anti–Phospho-Myosin Light Chain 2 (Ser19) antibody was from Cell Signaling Technology (#3671); monoclonal anti–α-tubulin was from Sigma-Aldrich (T9026); anti–glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was from Life Technologies (Invitrogen); rabbit immunoglobulin G (IgG; sc-2027); and mouse IgG (sc-2025) were from Santa Cruz Biotechnology. .. The horseradish peroxidase secondary antibodies polyclonal antibody against FLAG and polyclonal antibody against HA were from Sigma-Aldrich.

    Article Title: Stiff substrates increase YAP-signaling-mediated matrix metalloproteinase-7 expression
    Article Snippet: .. Materials YAP antibody (Cell Signaling Technology, Inc., Danvers, MA, USA) and Phospho-Myosin Light Chain 2 (Thr18/Ser19) antibody (Cell Signaling Technology, Inc.) were used for immunofluorescence and western blotting. .. Western blotting antibodies that were specific for CD29 (integrin-β1) and CD49b (integrin-α2) were purchased from BD Biosciences (San Jose, CA, USA).

    Incubation:

    Article Title: Myosin Light Chain Kinase (MLCK) Regulates Cell Migration in a Myosin Regulatory Light Chain Phosphorylation-independent Mechanism
    Article Snippet: .. After fixation and the blocking procedure, cell lines were incubated with the following antibodies as needed: anti-phospho-histone H3 (Ser-10) (PH3; Cell Signaling Technologies, dilution 1:100), anti-phospho-myosin light chain 2 (Ser-19) (p-RLC; Cell Signaling Technologies, dilution 1:200), anti-phospho-myosin light chain 2 (Thr-18/Ser-19) (2p-RLC; Cell Signaling Technologies, dilution 1:200), anti-smooth muscle α-actin (SMA; Thermo Fisher Scientific, dilution 1:250), anti-smooth muscle myosin heavy chain (SMMHC; Sigma-Aldrich, dilution 1:300), anti-MLCK (clone K36) (Sigma-Aldrich, dilution 1:100), anti-focal adhesion kinase (FAK; Bioworld, dilution 1:250), anti-myosin IIA (Cell Signaling Technologies, dilution 1:150), and anti-myosin IIB (Cell Signaling Technologies, dilution 1:200). .. For detection, appropriate secondary antibodies (diluted 1:250 in PBS containing 5% NGS) conjugated to Alexa Fluor 488, 555, or 633 (Molecular Probes, Invitrogen) were used.

    Immunocytochemistry:

    Article Title: Rap1 potentiates endothelial cell junctions by spatially controlling myosin II activity and actin organization
    Article Snippet: .. Materials and antibodies Materials were purchased as follows: FSK and latrunculin A from EMD Millipore; 8-pCPT-2’-O -methyl-cAMP (referred to as 007) from Tocris Bioscience; 6-Bnz from Biolog Life Science Institute; (R)-(+)-trans-N -(4-pyridyl)-4-(1-aminoethyl)-cyclohexanecarboxamide 2HCl H2 O (Y27632) from Wako Pure Chemicals; (−)-blebbistatin from Sigma-Aldrich; exoenzyme C3 transferase (C3 toxin) from Cytoskeleton, Inc.; and Cellmatrix type I-C from Nitta Gelatin Inc. Antibodies used here were purchased as follows: mouse anti–VE-cadherin and anti-Cdc42 from BD; anti-Rap1 from Santa Cruz Biotechnology, Inc.; anti-FGD5 for immunocytochemistry (#HPA019191), anti–β-actin, and anti-FLAG (M2) from Sigma-Aldrich; rabbit anti–VE-cadherin, anti–NM-IIA, anti–NM-IIB, anti–phospho-RLC at Ser19 (#3671), anti–phospho-RLC at Thr18/Ser19 (#3678), anti-cAMP response element–binding protein (CREB), and anti–phospho-CREB at Ser133 from Cell Signaling Technology; anti-MRCKα from Abcam; anti-MRCKβ from Kazusa DNA Research Institute; anti-FGD5 for Western blotting (#H00152273) from Abnova; mouse and rabbit control IgG from Vector Laboratories; Alexa Fluor 488– or Alexa Fluor 633–labeled goat anti–mouse and anti–rabbit IgG from Invitrogen; and HRP-coupled goat anti–mouse and anti–rabbit IgG from GE Healthcare. .. Rhodamine-phalloidin was purchased from Invitrogen.

    Immunofluorescence:

    Article Title: Stiff substrates increase YAP-signaling-mediated matrix metalloproteinase-7 expression
    Article Snippet: .. Materials YAP antibody (Cell Signaling Technology, Inc., Danvers, MA, USA) and Phospho-Myosin Light Chain 2 (Thr18/Ser19) antibody (Cell Signaling Technology, Inc.) were used for immunofluorescence and western blotting. .. Western blotting antibodies that were specific for CD29 (integrin-β1) and CD49b (integrin-α2) were purchased from BD Biosciences (San Jose, CA, USA).

    Blocking Assay:

    Article Title: Myosin Light Chain Kinase (MLCK) Regulates Cell Migration in a Myosin Regulatory Light Chain Phosphorylation-independent Mechanism
    Article Snippet: .. After fixation and the blocking procedure, cell lines were incubated with the following antibodies as needed: anti-phospho-histone H3 (Ser-10) (PH3; Cell Signaling Technologies, dilution 1:100), anti-phospho-myosin light chain 2 (Ser-19) (p-RLC; Cell Signaling Technologies, dilution 1:200), anti-phospho-myosin light chain 2 (Thr-18/Ser-19) (2p-RLC; Cell Signaling Technologies, dilution 1:200), anti-smooth muscle α-actin (SMA; Thermo Fisher Scientific, dilution 1:250), anti-smooth muscle myosin heavy chain (SMMHC; Sigma-Aldrich, dilution 1:300), anti-MLCK (clone K36) (Sigma-Aldrich, dilution 1:100), anti-focal adhesion kinase (FAK; Bioworld, dilution 1:250), anti-myosin IIA (Cell Signaling Technologies, dilution 1:150), and anti-myosin IIB (Cell Signaling Technologies, dilution 1:200). .. For detection, appropriate secondary antibodies (diluted 1:250 in PBS containing 5% NGS) conjugated to Alexa Fluor 488, 555, or 633 (Molecular Probes, Invitrogen) were used.

    Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 99
    Cell Signaling Technology Inc anti phospho myosin light chain ii antibody
    Changes in distribution of active <t>myosin</t> and traction forces after Gleevec treatment. Control <t>NBT-II</t> cells (A–C) or Gleevec-treated cells (D–F) that have been fixed, permeabilized and stained for phosphorylated myosin II <t>light</t> <t>chain</t> (p-MLC) to visualize active myosin localization (A and D) and Rhodamine-phalloidin to visualize the actin cytoskeleton (B and E). (C and F) Overlay images indicate the colocalization of actin bundles and p-MLC (red). The nucleus of the cell is stained with DAPI [60] . Bar = 20 µm. (G to J) Elastic substrate traction mapping of a control NBT-II cell (G and I) and Gleevec-treated NBT-II cell (H–J). (G and H) are the bead displacement maps and (I and J) are the traction maps where color bars indicate relative values (see Methods). The inset images in G and H are the phase image of the control cell and the Gleevec-treated cell. The white lines in G and H are outline of each cell. The inset images of figure I and J are the tractions magnified from indicated cell wings. Panel K is a calculation of the total cell traction force generated by cells ( Materials and Methods ). The value is normalized to total traction forces from control cells. The bar graph indicates NBTII cells treated with Gleevec generate considerably more total traction force than control NBTII cells. Error bars are standard deviation. Bar = 20 µm. 8 cells were examined for each case. Control and Gleevec-treated cells are significantly different in total cell traction force (* p
    Anti Phospho Myosin Light Chain Ii Antibody, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti phospho myosin light chain ii antibody/product/Cell Signaling Technology Inc
    Average 99 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    anti phospho myosin light chain ii antibody - by Bioz Stars, 2020-09
    99/100 stars
      Buy from Supplier

    95
    Cell Signaling Technology Inc phosphorylated myosin light chain 2
    Distribution of di-phosphorylated myosin light <t>chain</t> 2 (di-pMLC) and myosin IIB. Optical sections of 1 μm from the attached retina of the operated eye (DC). ( A–C ) Labeling for di-pMLC is present in the GCL, INL, OPL, and photoreceptors IS and OS. Double-staining with SV2 antibody shows colocalization of di-pMLC and SV2 in the OPL ([ C ] arrows ). The section also showed some axonal retraction ( arrowheads ) by photoreceptors into the ONL. ( D ) Control section shows little background labeling. ( E ) Myosin IIB ( green ) is distributed throughout the neural retina with stronger expression levels in the GCL, OPL, and OLM. Arrows indicate areas of colocalization ( yellow ) of myosin IIB ( green ) and di-pMLC ( red ) in the GCL, INL, and OPL. Nuclei were stained with TO-PRO3 ( blue ). ( F ) Western blot analysis from two animals suggested that expression of myosin IIB did not change in the detached retina compared to that in other retinal regions after 2 hours.
    Phosphorylated Myosin Light Chain 2, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 95/100, based on 6 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/phosphorylated myosin light chain 2/product/Cell Signaling Technology Inc
    Average 95 stars, based on 6 article reviews
    Price from $9.99 to $1999.99
    phosphorylated myosin light chain 2 - by Bioz Stars, 2020-09
    95/100 stars
      Buy from Supplier

    91
    Cell Signaling Technology Inc phospho myosin light chain 2
    Thrombin activates acto-myosin interaction by phosphorylation of myosin light <t>chain-2</t> (MLC2). (A) Immunocytochemistry of PAR1 (red) and phosphorylated MLC2 (Ser19, green) in human myometrial cells. (B, C) Immunoblots of phosphorylated MLC2 (p-MLC2), total MLC2, and β-actin of myometrial cells. Myometrial cells were treated with thrombin (2 U/mL) as a function of time (B) , or pretreated with 100 nM PAR1 inhibitor (SCH79797) for 1 h, and then treated with 2 U/mL of thrombin for 30 min (C) . The experiments were repeated three times.
    Phospho Myosin Light Chain 2, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 91/100, based on 23 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/phospho myosin light chain 2/product/Cell Signaling Technology Inc
    Average 91 stars, based on 23 article reviews
    Price from $9.99 to $1999.99
    phospho myosin light chain 2 - by Bioz Stars, 2020-09
    91/100 stars
      Buy from Supplier

    Image Search Results


    Changes in distribution of active myosin and traction forces after Gleevec treatment. Control NBT-II cells (A–C) or Gleevec-treated cells (D–F) that have been fixed, permeabilized and stained for phosphorylated myosin II light chain (p-MLC) to visualize active myosin localization (A and D) and Rhodamine-phalloidin to visualize the actin cytoskeleton (B and E). (C and F) Overlay images indicate the colocalization of actin bundles and p-MLC (red). The nucleus of the cell is stained with DAPI [60] . Bar = 20 µm. (G to J) Elastic substrate traction mapping of a control NBT-II cell (G and I) and Gleevec-treated NBT-II cell (H–J). (G and H) are the bead displacement maps and (I and J) are the traction maps where color bars indicate relative values (see Methods). The inset images in G and H are the phase image of the control cell and the Gleevec-treated cell. The white lines in G and H are outline of each cell. The inset images of figure I and J are the tractions magnified from indicated cell wings. Panel K is a calculation of the total cell traction force generated by cells ( Materials and Methods ). The value is normalized to total traction forces from control cells. The bar graph indicates NBTII cells treated with Gleevec generate considerably more total traction force than control NBTII cells. Error bars are standard deviation. Bar = 20 µm. 8 cells were examined for each case. Control and Gleevec-treated cells are significantly different in total cell traction force (* p

    Journal: PLoS ONE

    Article Title: Gleevec, an Abl Family Inhibitor, Produces a Profound Change in Cell Shape and Migration

    doi: 10.1371/journal.pone.0052233

    Figure Lengend Snippet: Changes in distribution of active myosin and traction forces after Gleevec treatment. Control NBT-II cells (A–C) or Gleevec-treated cells (D–F) that have been fixed, permeabilized and stained for phosphorylated myosin II light chain (p-MLC) to visualize active myosin localization (A and D) and Rhodamine-phalloidin to visualize the actin cytoskeleton (B and E). (C and F) Overlay images indicate the colocalization of actin bundles and p-MLC (red). The nucleus of the cell is stained with DAPI [60] . Bar = 20 µm. (G to J) Elastic substrate traction mapping of a control NBT-II cell (G and I) and Gleevec-treated NBT-II cell (H–J). (G and H) are the bead displacement maps and (I and J) are the traction maps where color bars indicate relative values (see Methods). The inset images in G and H are the phase image of the control cell and the Gleevec-treated cell. The white lines in G and H are outline of each cell. The inset images of figure I and J are the tractions magnified from indicated cell wings. Panel K is a calculation of the total cell traction force generated by cells ( Materials and Methods ). The value is normalized to total traction forces from control cells. The bar graph indicates NBTII cells treated with Gleevec generate considerably more total traction force than control NBTII cells. Error bars are standard deviation. Bar = 20 µm. 8 cells were examined for each case. Control and Gleevec-treated cells are significantly different in total cell traction force (* p

    Article Snippet: Biosciences Pharmingen, San Diego, CA), anti-α-Tubulin Antibody (#2144; Cell Signaling Technology, Beverly, MA), anti-phospho-myosin Light Chain II antibody (against Ser19, #3671, Cell Signaling Technology, Beverly, MA), anti-Rac1 antibody (#2465; Cell Signaling Technology, Beverly, MA), anti-Cdc42 antibody (#2462; Cell Signaling Technology, Beverly, MA), anti-RhoA antibody(sc-418; Santa Cruz Biotechnology, Santa Cruz, MA).

    Techniques: Staining, Generated, Standard Deviation

    Distribution of di-phosphorylated myosin light chain 2 (di-pMLC) and myosin IIB. Optical sections of 1 μm from the attached retina of the operated eye (DC). ( A–C ) Labeling for di-pMLC is present in the GCL, INL, OPL, and photoreceptors IS and OS. Double-staining with SV2 antibody shows colocalization of di-pMLC and SV2 in the OPL ([ C ] arrows ). The section also showed some axonal retraction ( arrowheads ) by photoreceptors into the ONL. ( D ) Control section shows little background labeling. ( E ) Myosin IIB ( green ) is distributed throughout the neural retina with stronger expression levels in the GCL, OPL, and OLM. Arrows indicate areas of colocalization ( yellow ) of myosin IIB ( green ) and di-pMLC ( red ) in the GCL, INL, and OPL. Nuclei were stained with TO-PRO3 ( blue ). ( F ) Western blot analysis from two animals suggested that expression of myosin IIB did not change in the detached retina compared to that in other retinal regions after 2 hours.

    Journal: Investigative Ophthalmology & Visual Science

    Article Title: RhoA Signaling and Synaptic Damage Occur Within Hours in a Live Pig Model of CNS Injury, Retinal Detachment

    doi: 10.1167/iovs.16-19447

    Figure Lengend Snippet: Distribution of di-phosphorylated myosin light chain 2 (di-pMLC) and myosin IIB. Optical sections of 1 μm from the attached retina of the operated eye (DC). ( A–C ) Labeling for di-pMLC is present in the GCL, INL, OPL, and photoreceptors IS and OS. Double-staining with SV2 antibody shows colocalization of di-pMLC and SV2 in the OPL ([ C ] arrows ). The section also showed some axonal retraction ( arrowheads ) by photoreceptors into the ONL. ( D ) Control section shows little background labeling. ( E ) Myosin IIB ( green ) is distributed throughout the neural retina with stronger expression levels in the GCL, OPL, and OLM. Arrows indicate areas of colocalization ( yellow ) of myosin IIB ( green ) and di-pMLC ( red ) in the GCL, INL, and OPL. Nuclei were stained with TO-PRO3 ( blue ). ( F ) Western blot analysis from two animals suggested that expression of myosin IIB did not change in the detached retina compared to that in other retinal regions after 2 hours.

    Article Snippet: The following antibodies were used: RhoA rabbit monoclonal antibody (mAb), phosphorylated myosin light chain 2 (pMLC [Ser-19]) mouse mAb, myosin light chain 2 (MLC) rabbit mAb and protein kinase C alpha (PKCα) rabbit polyclonal antibody (pAb) (all from Cell Signaling, Boston, MA, USA), di-phosphorylated MLC 2 (di-pMLC [Thr-18/Ser-19]) rabbit mAb (Thermo Scientific, Rockford, IL, USA), RAC1 mouse mAb (Becton Dickinson, Franklin Lakes, NJ, USA), p-CPI-17 rabbit pAb (Santa Cruz Biotechnology, Dallas, TX, USA), synaptic vesicle protein 2 (SV2) and myosin IIB mouse mAb (Developmental Studies Hybridoma Bank, Iowa City, IA, USA), and glial fibrillary acidic protein (GFAP) rabbit pAb (Dako, Carpinteria, CA, USA).

    Techniques: Labeling, Double Staining, Expressing, Staining, Western Blot

    Thrombin activates acto-myosin interaction by phosphorylation of myosin light chain-2 (MLC2). (A) Immunocytochemistry of PAR1 (red) and phosphorylated MLC2 (Ser19, green) in human myometrial cells. (B, C) Immunoblots of phosphorylated MLC2 (p-MLC2), total MLC2, and β-actin of myometrial cells. Myometrial cells were treated with thrombin (2 U/mL) as a function of time (B) , or pretreated with 100 nM PAR1 inhibitor (SCH79797) for 1 h, and then treated with 2 U/mL of thrombin for 30 min (C) . The experiments were repeated three times.

    Journal: PLoS ONE

    Article Title: Mechanisms of thrombin-Induced myometrial contractions: Potential targets of progesterone

    doi: 10.1371/journal.pone.0231944

    Figure Lengend Snippet: Thrombin activates acto-myosin interaction by phosphorylation of myosin light chain-2 (MLC2). (A) Immunocytochemistry of PAR1 (red) and phosphorylated MLC2 (Ser19, green) in human myometrial cells. (B, C) Immunoblots of phosphorylated MLC2 (p-MLC2), total MLC2, and β-actin of myometrial cells. Myometrial cells were treated with thrombin (2 U/mL) as a function of time (B) , or pretreated with 100 nM PAR1 inhibitor (SCH79797) for 1 h, and then treated with 2 U/mL of thrombin for 30 min (C) . The experiments were repeated three times.

    Article Snippet: A membrane was incubated with primary antibodies overnight at 4°C as follows: Phospho-Myosin Light Chain 2 (Ser19, Cell Signaling, #3671, RRID: AB_330248, 1:1000), myosin light chain 2 (D18E2, Cell Signaling, #8505, RRID: AB_2728760, 1:1000), Phospho-MYPT1 (Thr696, Cell Signaling, #5163, RRID: AB_10691830, 1:1000), Phospho-MYPT1 (Thr853, Cell Signaling, #4563, RRID: AB_1031185, 1:1000) MYPT1 (D6C1, Cell Signaling, #8574, RRID: AB_10998518, 1:1000) or anti-beta actin (Abcam, ab8227, 1:2000).

    Techniques: Immunocytochemistry, Western Blot